Gainers & Losers Of Aug.10: SGMO, VTVT, EDIT, ACRS, CEMP...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of August 10, 2017.

GAINERS

1. Sangamo Therapeutics Inc. (SGMO)

Gained 12.43% to close Thursday's (Aug.10) trading at $9.50.

News: The Company reported a narrower loss and higher revenue for the second quarter ended June 30, 2017.

For the recent second quarter, Sangamo's consolidated net loss is $12.5 million or $0.17 per share on revenue of $8.3 million. This compared with a net loss of $26.6 million or $0.38 per share and revenue of $3.7 million for the same period in 2016. Analysts polled by Thomson Reuters expected the Company to incur a loss of $0.19 per share and revenue of $5.98 million.

As of June 30, 2017, the Company had cash of $266.5 million.

2. vTv Therapeutics Inc. (VTVT)

Gained 10.97% to close Thursday's trading at $4.25.

News: No news

Near-term catalysts:

-- The top-line results from Part A of phase III study of Azeliragon in Alzheimer's diseases, dubbed STEADFAST, are expected to be reported in early 2018. -- Data from Part B of the STEADFAST study are anticipated to be read out in late 2018.

On June 27, 2017, the Company was notified that it is not in compliance with the requirement of NASDAQ Rule 5450(b)(2)(A) - with its market value being below $50 million for 30 consecutive business days.

The Company has 180 calendar days, or until December 26, 2017, to regain compliance. If it is unable to regain compliance within the grace period, the Company intends to transfer the listing of the Class A Common Stock to the NASDAQ Capital Market from the NASDAQ Global Market.

3. Galapagos NV (GLPG)

Gained 10.78% to close Thursday's trading at $81.06.

News: The Company announced positive topline results from its phase 2a trial of GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF).

In the trial, dubbed FLORA, over the 12-week period, patients receiving GLPG1690 showed an FVC (forced vital capacity) increase of 8 mL, which is of statistical significance, while patients on placebo showed an expected FVC reduction of 87 mL (mean from baseline).

The Company plans to rapidly progress GLPG1690 in a late stage trial and had already discussions with regulators regarding trial design.

4. Impax Laboratories Inc. (IPXL)

Gained 9.97% to close Thursday's trading at $18.20.

News: The Company reported solid revenue results for the second quarter of 2017.

On an adjusted basis, net income was $13.1 million or $0.18 per share in the second quarter 2017 compared to $15.0 million or $0.21 per share in the prior year period. Total revenues in the second quarter 2017 were $202.1 million, an increase of 17.1%, compared to $172.6 million in the prior year period, driven by a 24.0% increase in generic product sales.

For full year 2017, the Company foresees adjusted net income per share of $0.55 to $0.70. The adjusted EPS in 2016 were $1.16.

5. Editas Medicine Inc. (EDIT)

Gained 9.68% to close Thursday's trading at $19.72.

News: No news

Recent event:

On August 9, the Company announced that it achieved a second milestone under its collaboration with Juno Therapeutics, Inc. (JUNO). The milestone is related to the Company's technical progress towards overcoming the tumor microenvironment.

Editas Medicine and Juno Therapeutics are pursuing three research programs combining Editas Medicine's genome editing platform with Juno's CAR and TCR technologies in a deal worth over $700 million.

6. BioScrip Inc. (BIOS)

Gained 6.57% to close Thursday's trading at $3.08.

News: No news

Recent event:

On August 8, 2017, the Company reported second quarter 2017 financial results.

Net loss from continuing operations in the recent second quarter widened to $28.7 million or $0.26 per share on revenue of $218 million. This compares with a net loss from continuing operations of $8.3 million or $0.14 per share and revenue of $232.5 million in the year-earlier quarter.

Looking ahead to 2017, the Company expects revenue for the year to range between $815.0 million and $835.0 million. Last year, the Company reported revenue of $935.6 million.

7. Obalon Therapeutics Inc. (OBLN)

Gained 6.55% to close Thursday's trading at $9.27.

News: No news

Recent event:

On August 2, 2017, the Company reported Q2, 2017 financial results.

Net loss in the recent second quarter was $7.7 million or $0.46 per share on revenue of $2.0 million. This compared with a net loss of $4.1 million or $7.15 per share and revenue of $0.8 million in the second quarter of 2016.

Obalon is a medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity.

LOSERS

1. Kura Oncology, Inc. (KURA)

Lost 28.02% to close Thursday's trading at $6.55.

News: The Company has commenced an underwritten public offering, subject to market and other conditions, to issue and sell up to 5.3 million shares of its common stock.

The Company expects to grant the underwriters a 30-day option to purchase up to an additional 795,000 shares of its common stock.

2. Apollo Endosurgery Inc. (APEN)

Lost 25.80% to close Thursday's trading at $4.20.

News: No news

Recent event:

On August 1, 2017, the Company reported second quarter 2017 financial results.

Net loss for the recent second quarter was $6.9 million or $0.64 per share compared to a net loss of $9.5 million or $35.30 per share in the year-ago quarter. Revenue for the second quarter of 2017 declined slightly to $17.1 million from $17.34 million in the year-earlier period.

The Company deals with less invasive medical devices for bariatric and gastrointestinal procedures.

3. Ovid Therapeutics Inc. (OVID)

Lost 16.35% to close Thursday's trading at $5.32.

News: The Company reported financial results for the second quarter ended June 30, 2017 and provided an overview of its recent business progress.

The Q2, 2017 net loss attributable to common stockholders widened to $10.2 million or $0.57 per share from $5.4 million or $0.55 per share in the year-ago quarter.

As of June 30, 2017, Ovid had cash of $106.1 million.

The Company made its debut on the NASDAQ Global Select Market on May 5, 2017, offering its shares at a price of $15.00 each.

Pipeline:

The lead drug candidate of the Company is OV101, a potential treatment for Angelman syndrome and Fragile X syndrome. A phase II clinical trial of OV101 in adults with Angelman syndrome, dubbed STARS, and a phase I trial of OV101 in adolescents diagnosed with Angelman syndrome or Fragile X syndrome are underway.

Near-term catalysts: -- The company expects top line data from the STARS trial to be available in 2018. -- The top line data from the phase I trial evaluating OV101 in adolescents diagnosed with Angelman syndrome or Fragile X syndrome are expected to be available in the second half of 2017.

4. Audentes Therapeutics Inc. (BOLD)

Lost 15.34% to close Thursday's trading at $16.56.

News: The Company reported financial results for the quarter ended June 30, 2017.

The net loss was $22.7 million or $0.87 per share for the second quarter of 2017 compared to a net loss of $14.2 million or $6.43 per share for the same period in 2016.

As of June 30, 2017, Audentes had cash of $145.0 million.

Near-term catalysts:

-- Commence enrollment in a phase I/II study of AT132 of X-Linked Myotubular Myopathy patients less than five years of age, dubbed ASPIRO, in the third quarter of 2017. -- Report preliminary data from a phase I/II run-in study of AT132 in children living with X-Linked Myotubular Myopathy, known as INCEPTUS, in September 2017. -- Report preliminary clinical data from ASPIRO by the end of 2017. -- Commence enrollment in phase I/II study of AT342 for Crigler-Najjar Syndrome patients greater than one year of age, dubbed VALENS, in the third quarter of 2017. -- Report preliminary data from a phase I/II run-in study of AT342, dubbed LUSTRO, in October 2017. -- Report preliminary clinical data from VALENS by the end of 2017. -- File IND with the FDA for AT307 in CASQ2-CPVT, a rare monogenic disease that is characterized by life-threatening arrhythmias that may lead to sudden cardiac death. -- File IND with the FDA for AT982 in Pompe Disease in the first half of 2018.

5. Aclaris Therapeutics Inc. (ACRS)

Lost 14.65% to close Thursday's trading at $23.02.

News: The Company has offered to sell 3.26 million shares of its common stock to the public at a price of $23.02 per share.

The underwriters have been granted a 30-day option to purchase up to 489,000 additional shares of common stock at the public offering price, less the underwriting discount.

The net proceeds from the offering to Aclaris are expected to be $70.3 million. The offering is expected to close on or about August 16, 2017.

6. Cempra Inc. (CEMP)

Lost 14.38% to close Thursday's trading at $3.12.

News: Cempra and Melinta Therapeutics have entered into a definitive agreement under which Melinta will merge with Cempra. The combined NASDAQ-listed company will be named Melinta Therapeutics.

The current Cempra shareholders will own approximately 48 percent of the combined company and current Melinta shareholders will own approximately 52 percent of the combined company. The merger is expected to close in the fourth quarter of 2017.

7. Synergy Pharmaceuticals Inc. (SGYP)

Lost 13.03% to close Thursday's trading at $3.07.

News: No news

On August 9, 2017, the Company reported Q2, 2017 financial results.

The net loss for the recent second quarter widened to $73.9 million or $0.33 per share from $38.6 million or $0.23 per share in the year-ago quarter due to higher expenses that reflect the cost of marketing and promotional activities to support the product launch of TRULANCE on March 20, 2017.

Net sales, primarily related to TRULANCE, were $2.3 million in the second quarter of 2017 compared to nil revenue in the year-earlier period.

Near-term catalyst:

-- The sNDA for TRULANCE for the treatment of adults with constipation-predominant irritable bowel syndrome (IBS-C) is under FDA review - with a decision date set for January 24, 2018. Trulance is approved for the treatment of chronic idiopathic constipation in adults.